Identification of glypican-3 as a novel tumor marker for melanoma

被引:139
作者
Nakatsura, T
Kageshita, T
Ito, S
Wakamatsu, K
Monji, M
Ikuta, Y
Senju, S
Ono, T
Nishimura, Y
机构
[1] Kumamoto Univ, Grad Sch Med Sci, Dept Immunogenet, Kumamoto 8608556, Japan
[2] Kumamoto Univ, Grad Sch Med Sci, Dept Dermatol, Kumamoto 8608556, Japan
[3] Fujita Hlth Univ, Sch Hlth Sci, Dept Chem, Toyoake, Aichi 47011, Japan
关键词
D O I
10.1158/1078-0432.CCR-04-0348
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: We reported recently the novel tumor marker glypican-3 (GPC3) for hepatocellular carcinoma. In the present study, we investigated the expression of GPC3 in human melanoma cell lines and tissues and asked whether GPC3 could be a novel tumor marker for melanoma. Experimental Design: Expression of GPC3 mRNA and protein was investigated in human melanoma cell lines and tissues using reverse transcription-PCR and immunohistochemical analysis. Secreted GPC3 protein was quantified using ELISA in culture supernatants of melanoma cell lines and in sera from 91 patients with melanoma and 28 disease-free patients after surgical removal of primary melanoma. All of the subjects were Japanese nationals. Results: In >80% of melanoma and melanocytic nevus, there was evident expression of GPC3 mRNA and protein. Furthermore, GPC3 protein was evidenced in sera of 39.6% (36 of 91) of melanoma patients but not in sera from subjects with large congenital melanocytic nevus (0 of 5) and from healthy donors (0 of 60). Twenty-seven of 36 serum GPC3-positive patients were negative for both serum 5-S-cysteinyl-dopa and melanoma-inhibitory activity, well-known tumor markers for melanoma. The positive rate of serum GPC3 (39.6%) was significantly higher than that of 5-S-cysteinyldopa (26.7%) and of melanoma-inhibitory activity (20.9%). Surprisingly, we detected serum GPC3 even in patients with stage 0 in situ melanoma. The positive rate of serum GPC3 at stage 0, I, and II (44.4%, 40.0%, and 47.6%) was significantly higher than that of 5-S-eysteinyldopa (0.0%, 8.0%, and 10.0%). Also observed was the disappearance of GPC3 protein in sera from 11 patients after surgical removal of the melanoma. Conclusions: GPC3 is apparently a novel tumor marker useful for the diagnosis of melanoma, especially in early stages of the disorder.
引用
收藏
页码:6612 / 6621
页数:10
相关论文
共 41 条
[1]   Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].
Balch, CM ;
Buzaid, AC ;
Soong, SJ ;
Atkins, MB ;
Cascinelli, N ;
Coit, DG ;
Fleming, ID ;
Gershenwald, JE ;
Houghton, A ;
Kirkwood, JM ;
McMasters, KM ;
Mihm, MF ;
Morton, DL ;
Reintgen, DS ;
Ross, MI ;
Sober, A ;
Thompson, JA ;
Thompson, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648
[2]  
Bosserhoff AK, 1997, CANCER RES, V57, P3149
[3]   Serological markers for melanoma [J].
Brochez, L ;
Naeyaert, JM .
BRITISH JOURNAL OF DERMATOLOGY, 2000, 143 (02) :256-268
[4]  
Cano-Gauci DF, 1999, J CELL BIOL, V146, P255
[5]   Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma [J].
Capurro, M ;
Wanless, IR ;
Sherman, M ;
Deboer, G ;
Shi, W ;
Miyoshi, E ;
Filmus, J .
GASTROENTEROLOGY, 2003, 125 (01) :89-97
[6]  
Dong JL, 2003, CANCER RES, V63, P3883
[7]   OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth Syndrome, induces apoptosis in a cell line-specific manner [J].
Duenas-Gonzalez, A ;
Kaya, M ;
Shi, W ;
Song, H ;
Testa, JR ;
Penn, LZ ;
Filmus, J .
JOURNAL OF CELL BIOLOGY, 1998, 141 (06) :1407-1414
[8]   REPORT OF ANOTHER FAMILY WITH SIMPSON-GOLABI-BEHMEL SYNDROME AND A REVIEW OF THE LITERATURE [J].
GARGANTA, CL ;
BODURTHA, JN .
AMERICAN JOURNAL OF MEDICAL GENETICS, 1992, 44 (02) :129-135
[9]  
Gerl A, 1996, CLIN CANCER RES, V2, P1565
[10]  
Guadagni F, 2001, CLIN CANCER RES, V7, P2357